Literature DB >> 3122749

Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions.

Y Kuwana1, Y Asakura, N Utsunomiya, M Nakanishi, Y Arata, S Itoh, F Nagase, Y Kurosawa.   

Abstract

Chimeric genes composed of immunoglobulin (Ig)-derived variable (V) regions and T-cell receptor (TCR)-derived constant (C) regions were constructed. The VL and VH genes showing anti-phosphorylcholine (PC) activity were used in this study. Two pairs of chimeric genes, VL-C beta and VH-C alpha genes, and VL-C alpha and VH-C beta genes, were inserted into an expression vector containing both Ecogpt and neo genes, and transfected into EL4 cells. Cells which express both chimeric receptor molecules were established. The activity of the transformants to the antigen was examined by using stopped-flow fluorometry. An increase in the concentration of cytoplasmic calcium ion was observed after addition of Staphylococcus pneumoniae R36A bacteria grown in the choline-containing medium which express PC molecules, but not after the PC-negative bacteria grown in the ethanolamine-containing medium.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3122749     DOI: 10.1016/0006-291x(87)90502-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  101 in total

Review 1.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Engineered secreted T-cell receptor alpha beta heterodimers.

Authors:  C Grégoire; N Rebaï; F Schweisguth; A Necker; G Mazza; N Auphan; A Millward; A M Schmitt-Verhulst; B Malissen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

Review 3.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

Review 4.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

Review 5.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

6.  The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors.

Authors:  Ryan Zander; Weiguo Cui
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 7.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 8.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

Review 10.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.